Oramed Pharmaceuticals Inc. (ORMP)
NASDAQ: ORMP · Real-Time Price · USD
2.310
0.00 (0.00%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Company Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
Its product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes; and ORA-D-013-1 and ORA-D-013-2, which have completed phase III clinical trial for the treatment of type 2 diabetes.
The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses.
Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
Oramed Pharmaceuticals Inc.
| Country | United States |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Nadav Kidron |
Contact Details
Address: 1185 Avenue of the Americas, 3rd Floor New York, New York 10036 United States | |
| Phone | 844 967 2633 |
| Website | oramed.com |
Stock Details
| Ticker Symbol | ORMP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001176309 |
| CUSIP Number | 68403P203 |
| ISIN Number | US68403P2039 |
| Employer ID | 98-0376008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Nadav Kidron Esq. | President, Chief Executive Officer and Executive Chairman |
| Avraham Gabay | Chief Financial Officer, Treasurer and Secretary |
| Dr. Miriam Kidron Ph.D. | Chief Scientific Officer and Director |
| Joshua Hexter | Chief Operating and Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 3, 2025 | 8-K | Current Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Feb 11, 2025 | 8-K | Current Report |
| Jan 22, 2025 | 8-K | Current Report |
| Jan 3, 2025 | 8-K | Current Report |
| Dec 17, 2024 | 8-K | Current Report |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Oct 29, 2024 | 8-K | Current Report |